|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Outcomes in refractory diffuse large B-cell lymphoma:results fromamulticenter real-world study in China显示文摘Background:Diffuse large B-cell lymphoma(DLBCL)patients refractory to rituximab-based immunochemotherapy have a dismal prognosis.However,the definition of refractory DLBCL remains inconsistent and no large cohort study data is available from Asian countries.To validate the definition and outcomes of refractory DLBCL in China,we conducted a multicenter,retrospective cohort study.Methods:The REtrospective AnaLysis of Treatment REspoNse of refractory DLBCL(REAL-TREND)study was performed using real-world data from 8 centers in China.DLBCL patients with curative intent were included in the REAL-TREND dataset.Overall survival(OS)was estimated using the Kaplan-Meier method and compared by the log-rank test.Due to heterogeneity in response rates among different centers,the response rates of refractory patients were pooled using random-effect models.Multivariate survival analysis was performed using the Cox regression model.Results:A total of 2778 DLBCL patients diagnosed between January,2010 and December,2015 were enrolled to this study.After validating previous definitions,the SCHOLAR-1 study was most suitable to define refractory DLBCL.The estimated 5-year cumulative incidence of refractory patients was 20%(95% confidence Interval[CI]=18%-22%).After the determination of refractory disease,overall response rate and complete remission rate were 30%(95%CI=22%-38%)and 9%(95%CI=4%-15%),respectively.Patients with either no response to immunochemotherapy or relapse within 12 months after stem-cell transplantation had inferior survival with a median OS of 5.9 months(95%CI=5.5-7.1 months)and 2-year OS rate of 16%(95%CI=12%-20%).International prognostic index score 4-5(hazard ratio[HR]=2.22;95%CI=1.47-3.35),central nervous systemrelapse(HR=1.43;95%CI=1.04-1.97),and best response status(HR=2.68;95%CI=1.42-5.03 for partial remission.HR=5.97,95%CI=3.21-11.11 for stable disease/progressive disease)were independent unfavorable prognostic factors.Conclusions:This is the first large-scale Asian cohort study focusing on outcomes of refractory DLBCL.The definition of the SCHOLAR-1 study identifies patients with homogenously inferior survival,thus is appropriate to select refractory DLBCL.Due to poor clinical outcomes in the rituximab era,patients with refractory DLBCL may be potential candidates for novel treatment modalities. | Shuo Wang Li Wang Jianda Hu Wenbin Qian Xi Zhang Yu Hu Qi Zhu Bobin Chen Depei Wu Chung-Chou H.Chang Pengpeng Xu Xiaoyun Zheng Juying Wei Yao Liu Guohui Cui Yong Tang Yan Ma Haiwen Huang Hongmei Yi Weili Zhao | 2021 | Cancer Communications2021，41，3： | 10 |
| 2 | Clinical risk score for invasive fungal diseases in patients with hematological malignancies undergoing chemotherapy:China Assessment of Antifungal Therapy in Hematological Diseases (CAESAR) study显示文摘Invasive fungal disease (IFD) is a major infectious complication in patients with hematological malignancies.In this study,we examined 4889 courses of chemotherapy in patients with hematological diseases to establish a training dataset (n=3500) by simple random sampling to develop a weighted risk score for proven or probable IFD through multivariate regression,which included the following variables: male patients,induction chemotherapy for newly diagnosed or relapsed disease,neutropenia,neutropenia longer than 10 days,hypoalbuminemia,central-venous catheter,and history of IFD.The patients were classified into three groups,which had low (0-10,~1.2%),intermediate (11-15,6.4%),and high risk (> 15,17.5%) of IFD.In the validation set (n=1389),the IFD incidences of the groups were ~1.4%,5.0%,and 21.4%.In addition,we demonstrated that antifungal prophylaxis offered no benefits in low-risk patients,whereas benefits were documented in intermediate (2.1% vs.6.6%,P=0.007) and high-risk patients (8.4% vs.23.3%,P=0.007).To make the risk score applicable for clinical settings,a pre-chemo risk score that deleted all unpredictable factors before chemotherapy was established,and it confirmed that anti-fungal prophylaxis was beneficial in patients with intermediate and high risk of IFD.In conclusion,an objective,weighted risk score for IFD was developed,and it may be useful in guiding antifungal prophylaxis. | Ling Wang Ying Wang Jiong Hu Yuqian Sun He Huang Jing Chen Jianyong Li Jun Ma Juan Li Yingmin Liang Jianmin Wang Yan Li Kang Yu Jianda Hu Jie Jin Chun Wang Depei Wu Yang Xiao Xiaojun Huang | 2019 | Frontiers of Medicine2019，13，3： | 10 |
| 3 | Comparison of efficacy between HLA6/6-and HLA3/6-matched haploidentical hematopoietic stem cell transplant in T-cell-replete transplants between parents and children显示文摘To compare the efficacy of HLA6/6-matched haploidentical hematopoietic stem cell transplant(haplo-HSCT) with that of HLA3/6-matched HSCT in T-cell-replete transplants, we recruited 27 consecutive recipients from multiple centers who received HLA6/6-matched haplo-HSCT from a parent or child donor between February 2010 and May 2016. A matched-pair analysis was designed. For each recipient from the study cohort, two recipients were randomly selected from the control cohort and matched(according to patient age, patient sex, disease type, disease status, donor age, donor sex, and recipient-donor relationship). No significant differences were found in hematopoietic recovery. The incidence of grade II–IV and III–IV acute graft versus host disease was similar(18.5% vs. 31.5%, P=0.216; 11.1% vs. 9.3%, P=0.792) in the HLA6/6 and HLA3/6 groups, respectively. The3-year cumulative incidence of relapse was 14.8% and 17.0%(P=0.800). The 3-year cumulative incidence of nonrelapse mortality was 12.1% and 17.6%(P=0.751). The estimated 3-year disease-free survival was 73.1% and 65.5%(P=0.489). The estimated 3-year overall survival was 74.7% and 74.0%(P=0.946). The data suggested the efficacy and safety of the HLA6/6-and the HLA3/6-matched haplo-HSCT between parents and children are comparable. That HLA-mismatch disparity is not correlated with T-cell-replete haplo-HSCT outcome was substantiated. | Wenjing Yu Yu Wang Depei Wu Qifa Liu Lanping Xu Xiaohui Zhang Kaiyan Liu Xiaojun Huang | 2019 | Science China(Life Sciences)2019，62，1： | 6 |
| 4 | Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01(a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma显示文摘Objective: This study aimed to compare the pharmacokinetic, pharmacodynamic and safety profiles of HLX01(a rituximab biosimilar) and reference rituximab sourced from China(Mab Thera?;rituximab-CN).Methods: Here we report the results of two phase 1 studies. In the phase 1 a, open-label, dose-escalation study(NCT03218072, CTR20140400), eligible patients received 250, 375 and 500 mg/m^(2) HLX01 sequentially at 7-day intervals, after confirming no dose-limiting toxicity(DLT). In the phase 1 b, double-blind study(NCT02584920,CTR20140764), eligible patients were given a single dose of 375 mg/m^(2) HLX01 or rituximab-CN. The primary endpoints included safety and tolerability parameters for the phase 1 a and the area under the plasma concentrationtime curve from time zero to day 91(AUC0-91 d) for the phase 1 b study. Equivalence was concluded if 90%confidence interval(90% CI) for the geometric least squares mean ratio(GLSMR) fell in the pre-specified equivalence criteria(80%-125%).Results: Between June 20, 2014 and January 5, 2015, 12 patients were enrolled in the phase 1 a study. The pharmacokinetics of HLX01 showed dose proportionality and accumulation to steady state. HLX01 was well tolerated, with no serious adverse events(AEs), discontinuations or DLTs. Between November 8, 2014 and August13, 2015, 87 eligible patients were enrolled in the phase 1 b study, including 43 who received HLX01 and 44 who were treated with rituximab-CN. The equivalence endpoint was met with GLSMR for AUC0-91 d being 89.6%(90% CI: 80.4%-99.8%). AEs, anti-drug antibodies, and CD19+ and CD20+ B lymphocyte counts were similar between the HLX01 and rituximab-CN treatment groups.Conclusions: Treatment with HLX01 was safe and well tolerated in Chinese patients with B-cell lymphoma.HLX01 and rituximab-CN have similar pharmacokinetic, pharmacodynamic and safety profiles. | Yuankai Shi Qingyuan Zhang Xiaohong Han Yan Qin Xiaoyan Ke Hang Su Li Liu Jinxiang Fu Jie Jin Jifeng Feng Xiaonan Hong Xiaohong Zhang Depei Wu Bin Jiang Xiaodong Dong | 2021 | Chinese Journal of Cancer Research2021，33，3： | 5 |
| 5 | Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy显示文摘Chimeric antigen receptor T-cell(CAR-T)therapy has greatly improved the disease remission rate and long-term survival rate of patients with relapsed/refractory hematological malignancies.[1-3]Currently,several commercial CAR-T products are available in the market and numerous CAR-T clinical trials have been conducted.Attention should be paid to the safety of CAR-T therapy.The main adverse effects of CAR-T therapy are cytokine release syndrome(CRS)and immune effector cell-associated neurotoxicity syndrome(ICANS).[4] | Heng Mei Fangping Chen Yue Han Ming Hou He Huang Xiaojun Huang Yuhua Li Aibin Liang Qifa Liu Ting Niu Jun Peng Wenbin Qian Yongping Song Jianxiang Wang Ying Wang Depei Wu Kailin Xu Linhua Yang Renchi Yang Lei Zhang Liansheng Zhang Xi Zhang Xiaohui Zhang Weili Zhao Weidong Han Yu Hu | 2022 | Chinese Medical Journal2022，，14： | 4 |
| 6 | Haploidentical hematopoietic cell transplantation for severe acquired aplastic anemia: a case-control study of post-transplant cyclophosphamide included regimen vs. anti-thymocyte globulin & colony-stimulating factor-based regimen显示文摘Dear Editor,Haploidentical allogeneic hematopoietic stem cell transplantation(haplo-HSCT),a curative therapy for severe aplastic anemia(SAA)patients,has been used clinically for decades.Two models,not involving ex vitro T-cell depletion,have been adopted for haplo-HSCT in patients with SAA.The first is referred to as the'Beijing protocol'(Xu et al.,2017),and comprises a conditioning regimen using busulfex(BU),cyclophosphamide(CY). | Lanping Xu Bin Fu Wenjing Wang Yajing Xu Depei Wu Shunqing Wang Qifa Liu Linghui Xia Sujun Gao Ming Jiang Jianmin Wang Xi Zhang Hai Bai Huiren Chen Chunfu Li Xiaojun Huang | 2020 | Science China(Life Sciences)2020，63，6： | 3 |
| 7 | 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma显示文摘Adoptive cellular immunotherapy with chimeric antigen receptor(CAR)T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkin lymphoma(B-NHL).With increasing approval of CAR T-cell products and advances in CAR T cell therapy,CAR T cells are expected to be used in a growing number of cases.However,CAR T-cell-associated toxicities can be severe or even fatal,thus compromising the survival benefit from this therapy.Standardizing and studying the clinical management of these toxicities are imperative.In contrast to other hematological malignancies,such as acute lymphoblastic leukemia and multiple myeloma,anti-CD19 CAR T-cell-associated toxicities in B-NHL have several distinctive features,most notably local cytokine-release syndrome(CRS).However,previously published guidelines have provided few specific recommendations for the grading and management of toxicities associated with CAR T-cell treatment for B-NHL.Consequently,we developed this consensus for the prevention,recognition,and management of these toxicities,on the basis of published literature regarding the management of anti-CD19 CAR T-cell-associated toxicities and the clinical experience of multiple Chinese institutions.This consensus refines a grading system and classification of CRS in B-NHL and corresponding measures for CRS management,and delineates comprehensive principles and exploratory recommendations for managing anti-CD19 CAR T-cell-associated toxicities in addition to CRS. | Ping Li Yang Liu Yun Liang Jian Bo Sujun Gao Yongxian Hu Yu Hu He Huang Xiaojun Huang Hongmei Jing Xiaoyan Ke Jianyong Li Yuhua Li Qifa Liu Peihua Lu Heng Mei Ting Niu Yongping Song Yuqin Song Liping Su Sanfang Tu Jianxiang Wang Depei Wu Zhao Wang Kailin Xu Zhitao Ying Qingming Yang Yajing Zhang Fengxia Shi Bin Zhang Huilai Zhang Xi Zhang Mingfeng Zhao Weili Zhao Xiangyu Zhao Liang Huang Jun Zhu Wenbin Qian Weidong Han Aibin Liang | 2023 | Cancer Biology & Medicine2023，20，2： | 3 |
| 8 | Adoptively transferred donor IL-17-producing CD4^(+) T cells augment, but IL-17 alleviates, acute graft-versus-host disease显示文摘The role of IL-17 and IL-17-producing CD4^(+) T cells in acute graft-versus-host disease(GVHD)has been controversial in recent mouse and human studies.We carried out studies in a murine acute GVHD model of fully major histocompatibility complex-mismatched myeloablative bone marrow transplantation.We showed that donor wild-type CD4^(+) T cells exacerbated acute GVHD compared with IL-17−/−CD4^(+) T cells,while IL-17 reduced the severity of acute GVHD.The augmentation of acute GVHD by transferred donor IL-17-producing CD4^(+) T cells was associated with increased Th1 responses,while IL-17 decreased the percentages of Th1 cells in the GVHD target organs.Furthermore,IL-17 reduced the infiltration of macrophages into the GVHD tissues.In vitro study showed that IL-17 could downregulate Th1 responses,possibly through inhibiting IL-12 production by donor macrophages.Depletion of macrophages in vivo diminished the protective effect of IL-17.Our results demonstrated the differential roles of adoptively transferred donor IL-17-producing CD4^(+) T cells and IL-17 in the same acute GVHD model. | Yifeng Cai Shoubao Ma Yuejun Liu Huanle Gong Qiao Cheng Bo Hu Yan Wu Xiao Yu Chen Dong Kai Sun Depei Wu Haiyan Liu | 2018 | Cellular & Molecular Immunology2018，15，3： | 3 |
| 9 | Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF/ATG and posttransplant cyclophosphamide:results from the Chinese Bone Marrow Transplantation Registry Group(CBMTRG)显示文摘This study compared G-CSF/ATG and PTCy in myeloablative haploidentical hematopoietic stem cell transplantation(haploHSCT)for hematologic malignancies between January 2013 and March 2018 reporting to the Chinese Bone Marrow Transplantation Registry Group(CBMTRG).For each PTCy,G-CSF/ATG subjects(1:4)were selected using the nested case-pair method.In total,220 patients including 176 in G-CSF/ATG group and 44 in PTCy group were analyzed.The incidences of 30-day neutrophil engraftment(88.6%vs.96.6%,P=0.001),90-day platelet engraftment(84.1%vs.94.2%,P=0.04),the median time to neutrophil engraftment(17 days vs.12 days,P=0.000)and platelet engraftment(22 days vs.17 days,P=0.001)were significantly inferior in PTCy group.The incidences of grades 2–4 and 3–4 acute graft-versus-host disease(GVHD),chronic GVHD and severe chronic GVHD were comparable.Among G-CSF/ATG and PTCy groups,the 3-year progression-free survival,overall survival,cumulative incidences of nonrelapse mortality and relapse was 74.3%vs.61%(P=0.045),78.3%vs.65.2%(P=0.039),12%vs.27.3%(P=0.008),and 14.9%vs.11.7%(P=0.61),respectively.G-CSF/ATG can achieve better engraftment,PFS and OS,and lower incidence of NRM compared to PTCy in myeloablative haplo-HSCT for hematologic malignancies. | Feifei Tang Yajing Xu Huiren Chen Lanping Xu Xiaohui Zhang Yu Wang Qifa Liu Depei Wu Xiaojun Huang | 2020 | Science China(Life Sciences)2020，63，4： | 3 |
| 10 | Clinical and serological characterization of autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation显示文摘 | Yang Zhen Wu Bangzhao Zhou Youning Wang Wenjuan Chen Suning Sun Aining Wu Depei Xu Yang | 2014 | Chinese Medical Journal2014，，7： | 3 |
| 11 | GAS2-Calpain2 axis contributes to the growth of leukemic cells显示文摘 | LUi Sun Haixia Zhou Hong Liu Yue Ge Xiuyan Zhang Wenjuan Ma Depei Wu Yun Zhao | 2015 | Acta Biochimica et Biophysica Sinica2015，47，10： | 2 |
| 12 | 2021 Chinese consensus on the diagnosis and management of primary immune thrombocytopenia in pregnancy显示文摘Immune thrombocytopenia(ITP)is an acquired disease characterized by isolated thrombocytopenia,which is one of the most common causes of thrombocytopenia during pregnancy.Women with ITP who have severe thrombocytopenia are at an increased risk for life-threatening obstetric complications.Therefore,we established this consensus statement on the diagnosis and management of ITP during pregnancy(detailed information is available in the Supplementary File,http://gffzz16e312a87a7141a5hx6pkuww5o5fn60on.ffgz.tsg.suse.edu.cn/A978). | Zhang Xiaohui Chen Fangping Chen Xiequn Cheng Yunfeng Fang Meiyun Feng Jianming Fu Haixia Gao Hong Han Yue He Aili Hou Ming Hu Yu Huang Ruibin Huang Wenrong Jing Zhicheng Kong Peiyan Liang Aibin Liang Meiying Liu Daihong Liu Junling Liu Lin Liu Xiaowei Ma Liangming Mei Heng Ni Heyu Niu Ting Peng Jun Qiao Jianlin Ren Jinhai Song Yongping Tang Liang V Tong Tong Wang Shaoyuan Wang Xin Wang Zhao Wei Hui Wu Depei Wu Guangsheng Xu Caigang Xu Xue Xu Yajing Yang Linhua Yang Renchi Yang Tonghua Yin Chenghong Yu Li Zhang Guangsen Zhang Lei Zhang Liansheng Zhang Xi Zhao Weili Zhao Yongqiang Zhou Daobin Zhou Hu Zhou Zeping Zhu Tienan Wang Jianliu Huang Xiaojun | 2022 | Chinese Medical Journal2022，，8： | 2 |
| 13 | ZFX modulates the growth of human leukemic cells via B4GALT1显示文摘锌手指蛋白质 X 连接(ZFX ) 是胚胎的干细胞(转换字符) 和造血的干细胞(HSC ) 的一个关键管理者,它被要求因为两个都槽口细胞内部的领域(NotchIC ) 在鼠标模型导致了尖锐 T 房间白血病和 MLL-AF9-induced myeloid 白血病。然而, ZFX 的角色和它在人的白血病的房间的内在的机制还仍然保持不清楚,尽管积累的数据证明了 ZFX 异常地在各种各样的人的肿瘤被表示并且起一个重要作用。此处,我们发现 ZFX 异常地与控制房间相比从白血病病人在各种各样的人的白血病的房间线和主要房间被表示。ZFX 的沉默包括 K562, Jurkat, Namalwa,和 THP-1 房间在各种各样的房间通过 deregulated 房间周期或 apoptosis 的正式就职导致了生长抑制。基因表示分析揭示了那 UDP 女郎: GlcNAc 1,4-galactosyltransferase,(B4GALT1 ) 多肽 1 在 ZFX silencing 之上是显著地下面调整的,它在对 imatinib mesylate (IM ) 的治疗的 K562 房间的反应被含有。另外, lectin 污点试金证明在 K562 房间的 glycoproteins 的 galactosylation 在 ZFX silencing 之上被压制。有趣地, B4GALT1 的 overexpression 恢复了生长并且授与药抵抗到沉默 ZFX 的细胞。一起拿,我们证明了 ZFX 异常地在多重人的白血病的房间被表示,它经由 B4GALT1 部分调制生长和白血病的房间的药反应,它建议 ZFX 是白血病的房间的一个新管理者并且在这些致命的疾病在这个 stemness 管理者上保证集中的调查。 | Jie Wu Lun Xiao Haixia Zhou Hong Liu Yue Ge Jing Yang Yuanyuan Li Depei Wu Yun Zhao Xiuyan Zhang | 2016 | Acta Biochimica et Biophysica Sinica2016，48，12： | 2 |
| 14 | The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia显示文摘 | Yanhui Liu Zhaoyue Wang Miao Jiang Lan Dai Wei Zhang Depei Wu Changgeng Ruan | 2010 | Leukemia Research2010，，7： | 1 |
| 15 | Vindesine induces rhabdomyolysis in patients with acute lymphoblastic leukemia显示文摘Rhabdomyolysis is a syndrome which involves myoglobin and other intracellular proteins and electrolytes that occurs from breakdown of skeletal muscleand leak into the circulation.1 The clinical symptoms of rhabdomyolysis include myalgia,tenderness on palpation,weakness,brown urine,fever,myoglobinuria,electrolyte imbalance,and acute renal failure.Rhabdomyolysis can be severe enough to be life threatening.2 The causes of rhabdomyolysis include alcohol,electrolyte imbalance (potassium,phosphorus,and magnesium depletion),viral myositis,trauma,connective tissue diseases,drug reaction,toxication,exercise,metabolic diseases,seizures,and hereditary enzyme deficiencies.The exact mechanisms underlying rhabdomyolysis are not fully understood,but it is clear that muscle damage can be caused by direct muscle injury or metabolic inequalities between energy production and energy consumption. | Liu Limin Sun Yumei Si Yejun Lin Guoqiang Zhang Xingxia Zhao Guangsheng Zhang Yanming Wu Depei | 2014 | Chinese Medical Journal2014，，21： | 1 |
| 16 | Acute T cells lymphoblastic leukemia associated with t(1;19)(q23;p13)/ E2A – PBX1 in an adult显示文摘 | Guangsheng He Depei Wu Xuhui Zhang Yao Li Chenzi Xin Ri Zhang | 2009 | Leukemia Research2009，，1： | 1 |
| 17 | High frequency of BTG1 deletions in patients with BCR/ABL1 positive acute leukemia显示文摘 | Jundan Xie Qian Wang Qinrong Wang Hong Yao Lijun Wen Liang Ma Depei Wu Suning Chen | 2014 | Cancer Genetics2014，，： | 1 |
| 18 | Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase显示文摘在酷氨酸 kinase 禁止者(TKI ) 时代, imatinib 在长期或加速的阶段是为有长期的 myeloid 白血病(电流型逻辑) 的病人的首要的治疗。尽管第二代的 TKI (TKI 2), 包括 dasatinib 和 nilotinib,为有进行了到的疾病的病人的适当治疗政体被加速阶段追随者 imatinib 治疗,造血的干细胞移植(allo-HSCT ) 是的 allogeneic 唯一的药品治疗。这研究回顾地在加速的阶段为电流型逻辑的治疗分析了 TKI 2 和 HSCT 的功效。有从 2001 年 2 月在中国电流型逻辑联盟数据库登记到 2014 年 2 月的电流型逻辑的 93 个病人被注册并且划分了成 TKI 2(n = 33 ) 并且 allo-HSCT (n = 60 ) 组。在 TKI 2 组, 26 和 7 个病人收到了分别地,同样起始的 TKI 2 和 11 个病人在失败以后转移了到其他的 TKI 2 到一 TKI 2 的 nilotinib 和 dasatinib。在 allo-HSCT 组, 22 (36.7%) , 35 (58.3%) ,并且 3 (10%) 病人们分别地从一个匹配 HLA 的兄弟施主, HLA mismatched/haploidentical 施主,和无关的施主经历了 allo-HSCT。在 HSCT 组的所有病人被嫁接。总的来说, 69.7% , 48.5% ,和 45.5% 病人介绍了 hematological,细胞发生、主要的分子的回答,分别地到至少一 TKI 2 。所有 60 个病人(100%) 在 HSCT 组完成了 CHR 和细胞发生的反应。在展出的 TKI 2 组的病人降低 5 年的全面幸存率(42.9% 对 86.4% , P = 0.002 ) , 5 年的没有事件的幸存率(14.3% 对 76.1% , P < 0.001 ) ,并且 5 年的没有前进的幸存(28.6% 对 78.1% , P < 0.001 ) 比那些在 allo-HSCT 组。Multivariate 分析证明男性和 TKI 2 治疗是差的全面幸存的预言者,而血红素 < 100 g/L 和 TKI 2 治疗是差的没有事件的幸存和没有前进的幸存的预言者。这些结果显示 allo-HSCT 可能为有在加速的阶段的电流型逻辑的成年病人比 nilotinib 和 dasatinib 优异。 | Lanping Xua Huanling Zhu Jianda Hu Depei Wu Hao Jiang Qian Jiang Xiaojun Huang | 2015 | Frontiers of Medicine2015，9，3： | 1 |
| 19 | Keratinocyte growth factor enhanced immune reconstitution in murine allogeneic umbilical cord blood cell transplant显示文摘 | Yi Wang Guanghua Chen Shumin Qiao Xiao Ma Xiaowen Tang Aining Sun Depei Wu | 2011 | Leukemia & Lymphoma2011，，8： | 1 |
| 20 | High stearic acid diet modulates gut microbiota and aggravates acute graft-versus-host disease显示文摘Dear Editor,Acute graft-versus-host disease(aGVHD)is the leading cause of transplantation-related mortality,and limits therapeutic benefits of allogeneic bone marrow transplantation(allo-BMT).New insight is needed into the development of aGVHD.Most nutritional metabolites contribute to host health and immune homeostasis. | Bingyu Yang Xianfeng Zhang Huanle Gong Yuhui Huang Chang Wang Haiyan Liu Chen Dong Shoubao Ma Xiaojin Wu Depei Wu | 2021 | Signal Transduction and Targeted Therapy2021，6，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员